Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Respuesta-adaptativa a Epcoritamab en primera recaída: estudio para evaluar la eficacia de ePtoritamab en pacientes con recaída/linfoma refractario de células B grandes (REPIFIR)

Respuesta-adaptativa a EPCoritamab en primer estudio de recaída: un estudio de fase II, ajuste de respuesta, abierta y multicéntrica para evaluar la eficacia de ePtoritamab en pacientes con recaída/linfoma de células B grandes refractarias

phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.

Descripción general del estudio

Descripción detallada

Epcoritamab is a full-length bispecific IgG1 antibody directed against two proteins, CD3 on the T lymphocyte and CD20 on the lymphoma cell. This antibody redirects and activates T cells, generating an immune synapse that eventually eliminates malignant cells expressing CD20.

Previous studies have demonstrated that Epcoritamab has potent antitumor activity as a monotherapy agent, with a favorable and manageable safety profile.

Since its efficacy is so favorable it is reasonable to think that it could be an excellent option for first-relapse patients. However, to date, there is no data on this therapy's usefulness as second-line treatment. Therefore we intend to evaluate the efficacy of Epcoritamab as a treatment option for patients with first-relapse LBCL.

The purpose of this study is to determine the efficacy of Epcoritamab as second line treatment for LBCL patients. On the basis of the clinical experience, it is hypothesized that Epcoritamab would provide a better complete response rate (CRR) in comparison to Platinum-based immunochemotherapy (CRR=25%), Polatuzumab-Bendamustin Rituximab (CRR=40%) and Tafasitamab-Lenalidomide (CRR=43%).

Tipo de estudio

Intervencionista

Inscripción (Estimado)

80

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Auxi Moreno
  • Número de teléfono: +34 683 636 850
  • Correo electrónico: amoreno@geltamo.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • Andalusia
      • Seville, Andalusia, España, 41013
        • Reclutamiento
        • Hospital Universitario Virgen del Rocío
        • Contacto:
    • Aragon
      • Zaragoza, Aragon, España, 50009
        • Reclutamiento
        • Hospital Universitario Miguel Servet
        • Contacto:
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, España, 07120
        • Reclutamiento
        • Hospital Universitario Son Espases
        • Contacto:
    • Castille and León
      • Burgos, Castille and León, España, 09006
        • Reclutamiento
        • Hospital Universitario de Burgos
        • Contacto:
      • Salamanca, Castille and León, España, 37007
        • Reclutamiento
        • Hospital Universitario de Salamanca
        • Contacto:
          • Alejandro Martín García-Sancho, MD
          • Número de teléfono: +34 923 291 100
          • Correo electrónico: amartingar@usal.es
    • Catalonia
      • Badalona, Catalonia, España, 08916
        • Reclutamiento
        • ICO Badalona
        • Contacto:
      • Barcelona, Catalonia, España, 08035
        • Reclutamiento
        • Hospital Universitari Vall d'Hebrón
        • Contacto:
    • Extremadura
      • Cáceres, Extremadura, España, 10003
        • Reclutamiento
        • Hospital San Pedro de Alcántara
        • Contacto:
    • Madrid
      • Madrid, Madrid, España, 28041
        • Reclutamiento
        • Hospital Universitario 12 de Octubre
        • Contacto:
          • Ana Jiménez Ubieto, MD
          • Número de teléfono: +34 917 792 809
          • Correo electrónico: anitiju@hotmail.com
      • Madrid, Madrid, España, 28007
        • Reclutamiento
        • Hospital General Universitario Gregorio Marañón
        • Contacto:
      • Madrid, Madrid, España, 28031
      • Madrid, Madrid, España, 28040
        • Reclutamiento
        • Hospital Universitario Fundación Jiménez Díaz
        • Contacto:
          • Raúl Córdoba
          • Número de teléfono: +34 915 504 880
          • Correo electrónico: raul.cordoba@fjd.es
    • Murcia
      • El Palmar, Murcia, España, 30120
        • Reclutamiento
        • Hospital Virgen de la Arrixaca
        • Contacto:
    • Málaga
      • Marbella, Málaga, España, 29603
        • Reclutamiento
        • Hospital Universitario Costa del Sol
        • Contacto:
    • Principality of Asturias
      • Oviedo, Principality of Asturias, España, 33011
        • Reclutamiento
        • Hospital Universitario Central de Asturias
        • Contacto:
    • Tenerife
      • San Cristóbal de La Laguna, Tenerife, España, 38320
        • Reclutamiento
        • Hospital Universitario de Canarias
        • Contacto:
    • Valencia
      • Valencia, Valencia, España, 46017
        • Reclutamiento
        • Hospital Universitario Dr. Peset
        • Contacto:
          • Eva María Donato
          • Número de teléfono: +34 963 189 168
          • Correo electrónico: donato_eva@gva.es
      • Valencia, Valencia, España, 46024
        • Reclutamiento
        • Hospital Universitario y Politécnico La Fe
        • Contacto:
    • Vizcaya
      • Bilbao, Vizcaya, España, 48013
        • Reclutamiento
        • Hospital Universitario de Basurto
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Written informed consent must be obtained before any study-specific assessment is performed.

  2. Age >18 years

  3. Patients with Relapse/Refractory histologically confirmed LBCL, including, Diffuse Large B Cell Lymphoma (DLBCL); Primary Mediastinal Large B Cell Lymphoma (PMBCL), High-grade B-cell lymphoma (HGBCL); and grade 3B Follicular Lymphoma.

    Relapsed disease is defined as complete remission to first line therapy followed by a recurrence of the disease after a minimum of 6 months of completion of first-line therapy. A biopsy at the time of relapse is recommended but not mandatory.

    Refractory disease is defined as no objective response to first line therapy (biopsy not mandatory if diagnostic sample available). Four groups of patients are eligible:

    • PD as best response to first line therapy.
    • SD as best response after at least 4 cycles of first line therapy.
    • PR as best response after at least 6 cycles of first line therapy.
    • CR and disease recurrence within < 6 months from the completion of first-line therapy.
  4. Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) or CHOP-like chemotherapy.

  5. At the investigator's discretion, the patient should not be a candidate for 1st relapse CAR-T therapy or unwilling to receive CAR-T therapy.

  6. Patients must be autologous stem cell transplantation (ASCT)-ineligible: Age ≥65 and/or HTC-CI ≥3 or or unwilling to receive transplant.

  7. PET positive disease.

  8. Performance status according to Eastern Cooperative Oncology Group (ECOG) 0 to 2.

  9. Patients meeting with the following hematology values:

    • Hemoglobin ≥8 g/dl (transfusion support permitted but not within 7 days of screening lab collection)
    • Absolute neutrophil count (ANC) ≥ 1/109/L (growth factor support allowed in case of bone marrow involvement).
    • Absolute lymphocyte count ≥ 0.1/109/L,
    • Platelet count ≥ 70/109/L (unless secondary to bone marrow involvement, OR ≥50x/109/L if documented bone marrow involvement). Platelet transfusions permitted but not within 7 days of screening lab collection.
  10. Female patients of child-bearing potential must have a negative urine or serum pregnancy test at screening and agree to use highly effective methods of contraception (e.g., established use of oral, injected or implanted combined (estradiol and progesterone containing) hormonal contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS) upon enrollment according to the recommendations provided by Clinical Trial Facilitation Group (CTFG), during the treatment period and for 4 months after the last dose of study medication. Moreover, the patient must agree to ongoing pregnancy testing during the course of the study, and after study therapy has ended. This applies even if the patient practices complete and continued sexual abstinence.

    Women not of childbearing potential are defined as: premenarchal; postmenopausal (greater than 50 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level greater than 40 IU per L or milli-International unit (mIU) per mL); permanently sterilized (e.g., bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy.

  11. Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential) upon enrollment according to the recommendations provided by CTFG, during the treatment period, and for 4 months following the last dose of investigational drug or agreement to remain abstinent. Agreement to refrain from donating blood or sperm during the study participation and for 4 months after the last dose of study medication.

  12. Women must agree not to donate blood or oocytes during the course of the study and for 4 months after the last dose of study medication. Restrictions concerning blood donation apply as well to females who are not of childbearing potential. Men must also not donate sperm during the trial and for 4 months after receiving the last dose of study drug.

  13. Females of childbearing potential must refrain from breastfeeding during the course of the study and for 4 months after the last dose of study medication.

  14. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

  15. Not included in other clinical trial or treated with an experimental drug.

Exclusion Criteria:

  1. Patients who received more than one prior line of systemic therapy

  2. Patients with detectable Central Nervous System (CNS) lymphoma

  3. Significant organ function impairment:

    • creatinine clearance calculated by Cockcroft-Gault ≤ 45 ml/min
    • direct bilirubin level < 2 x ULN (except in patients with Gilbert's syndrome),
    • alanine transaminase (ALT) and aspartate aminotransferase (AST) >3 × ULN or >5 × ULN in cases of documented liver involvement.
    • clinically relevant pleural effusion,
    • left ventricular ejection fraction (LVEF) ≤ 45%
  4. Serious accompanying disorder leading to impaired organ function causing significant clinical problems and reduced life expectancy of less than 3 months.

  5. Have a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period

  6. Known clinically significant cardiac disease, including:

    • Onset of unstable angina pectoris within 6 months of signing the patient informed consent form.
    • Acute myocardial infarction within 6 months of signing the patient informed consent form.
    • Congestive heart failure (grade III or IV as classified by the New York Heart Association.
    • Left ventricular ejection fraction ≤45%.
  7. Known past or current malignancy other than inclusion diagnosis, except for: Cervical carcinoma of Stage 1B or less; Non-invasive basal cell or squamous cell skin carcinoma; Non-invasive, superficial bladder cancer; Localized low grade prostate cancer (up to Gleason score 6); DCIS of the breast; Other malignancy that has been treated with curative intent and has remained in remission for 3 years.

  8. Previous ASCT.

  9. Prior anti-CD3 and CD20 bispecific antibodies therapy or prior treatment with tafasitamab.

  10. Presence of severe infection that is uncontrolled or requiring IV antimicrobials for management.

  11. History of HIV infection or acute or chronic active hepatitis B or C infection.

    • Individuals with positive HIV serology may be included if negative viral load and CD4 >200/mm3. For being included, patients should have controlled disease and been on treatment for at least 1 year
    • Individuals with history of hepatitis infection with positive antibodies (anti-HB and anti-HV) might be included if negative viral load (negative hepatitis B PCR). Patients who are HBcAb positive must receive HBV prophylaxis while on treatment. Patients with positive HbsAg are excluded. Patients who are hepatitis B PCR positive will be excluded. Patients who are hepatitis C RNA positive will be excluded.
  12. Females who are pregnant or breastfeeding.

  13. Richter's transformation or prior chronic lymphocytic leukemia (CLL).

  14. Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 4 weeks prior to Cycle 1 Day 1.

  15. Recent major surgery (within 4 weeks before the start of Cycle 1 Day 1) other than for diagnosis.

  16. Vaccination with a live vaccine or COVID-19 vaccination within 4 weeks prior to treatment.

  17. History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure. History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies.

  18. Close affiliation with the investigator (e.g. a close relative) or persons working at the study site.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: EPCO monotherapy

Epcoritamab in monotherapy will be administred until cycle 12.

Patients will receive 12 cycles of Epcoritamab monotherapy.

Experimental: Combination therapy

3 cycles of Epcoritamab in monotherapy will be administred and then Epcoritamab will be administred with Tafasitamab and Lenalidomide from cycle 4 until cycle 15.

Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Efficacy of Epcoritamab monotherapy
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR at any moment since initiation. The CRR will be assessed by PET-CT according to Lugano Classification and is defined as the proportion of patients who achieve a best response of complete response (CR) at any moment since initiation of Epcoritamab first administration.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Efficacy of Epcoritamab monotherapy after 3 cycles
Periodo de tiempo: At the end of cycle 3 (each cycle is 28 days)

The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR, defined as the proportion of patients who achieve a best response of CR after 3 cycles of Epcoritamab administration.

At the end of cycle 3 (each cycle is 28 days)
Efficacy of Epcoritamab monotherapy and combination therapy by CRR
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per CRR (locally evaluated for Epcoritamab monotherapy; local and central evaluation for combination therapy).

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
Evaluation of MRD
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

The efficacy of Epcoritamab monotherapy and combination therapy will be evaluated by MRD (positive or negative) from ctDNA samples immediately before initiation of C3, C4, C7, C10, C12, C13, C15, End of Treatment (EoT) and cycles 18/24 (epcoritamab monotherapy) or cycles 21/27 (combination therapy).

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Evaluation of patients with negative MRD by PFS
Periodo de tiempo: At cycle 3 visit (each cycle is 28 days).

The PFS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy).

At cycle 3 visit (each cycle is 28 days).
Safety and tolerability
Periodo de tiempo: Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).

The safety and tolerability of Epcoritamab monotherapy and combination therapy are evaluated as follows:

  • Type, frequency, and severity of adverse events (AEs).
  • Type, frequency, and severity of Adverse events of special interest (AESIs): Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), clinical tumor lysis syndrome (CTLS) and other safety topics of interest (tumour flare reaction, prolonged cytopenia, serious infections and second primary malignancies).
  • Incidence, severity, and treatment.
Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).
Efficacy of Epcoritamab Monotherapy and Combination therapy by ORR
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per ORR at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab Monotherapy and combination therapy by DoR
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoR at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab monotherapy and combination therapy by DoCR
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoCR at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab monotherapy and combination therapy by EFS
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per Event-free survival (EFS) at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab monotherapy and combination therapy by PFS
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per PFS at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab montherapy and combination therapy by OS
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per OS at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Evaluation of patients with negative MRD by OS
Periodo de tiempo: At cycle 3 visit (each cycle is 28 days).

The OS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy).

At cycle 3 visit (each cycle is 28 days).
Evaluation of patients with negative MRD by DoR
Periodo de tiempo: At cycle 3 visit (each cycle is 28 days).

The DoR of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy).

At cycle 3 visit (each cycle is 28 days).

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Response of patients stopping treatment by PFS
Periodo de tiempo: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).

To compare the PFS of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination.

At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
Correlation between biomarkers and study treatment by ORR
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by ORR.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by DoR
Periodo de tiempo: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).

Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by DoR in patients reintroducing the study treatment with a MRD positive result.

After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).
MRD negativity
Periodo de tiempo: through study completion, an average of 5 years

Median duration of molecular response (MRD negativity).

through study completion, an average of 5 years
Correlation between tumor volume and efficacy
Periodo de tiempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

Correlation between Total Metabolic Tumor Volume (centrally evaluated) and study treatment efficacy determined by PFS and OS.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
ctDNA levels
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Descriptive analysis of dynamic changes in ctDNA levels

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between lymphocyte subsets and efficacy
Periodo de tiempo: Through study completion, an average of 5 years.

Correlation between lymphocyte subsets and study treatment efficacy determined by ORR, CRR, DoR, PFS and OS and safety determined by type, frequency, and severity of adverse events.

Through study completion, an average of 5 years.
Response of patients stopping treatment
Periodo de tiempo: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).

To compare the DoR of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination.

At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy by CRR
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by CRR.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy DoR
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by DoR, PFS and OS.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy by PFS
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by PFS.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy by OS
Periodo de tiempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by OS.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by PFS
Periodo de tiempo: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)

Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by PFS in patients reintroducing the study treatment with a MRD positive result.

After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by OS
Periodo de tiempo: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)

Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by OS in patients reintroducing the study treatment with a MRD positive result.

After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Mariana Bastos-Oreiro, Hospital General Universitario Gregorio Marañon
  • Investigador principal: Pau Abrisqueta, Hospital Universitari Vall d'Hebrón

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de agosto de 2025

Finalización primaria (Estimado)

27 de diciembre de 2031

Finalización del estudio (Estimado)

27 de diciembre de 2031

Fechas de registro del estudio

Enviado por primera vez

10 de julio de 2025

Primero enviado que cumplió con los criterios de control de calidad

9 de agosto de 2025

Publicado por primera vez (Actual)

17 de agosto de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

29 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Data obtained through this study may be provided to qualified researchers with academic interest in hematology diseases. All individual data collected during the trial will be available. Data shared will be coded, with no PHI included. Study protocol, statistical analysis plan, informed consent form and clinical study report will be also available. Information will be available beginning 6 months after final publication with no end date established. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party. Data requests can be submitted starting 6 months after article publication. Access to trial IPD can be requested by qualified researchers and will be provided following review and approval of a research and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact to GELTAMO though the web page: https://www.geltamo.com/contacto

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir